Eli Lilly stock lifts 2026 outlook after strong third quarter
Published on 10/30/2026 at 16:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLilly raises outlook after strong quarter
- Third-quarter revenue rose 39 percent, supported by Mounjaro and Zepbound.
- Lilly lifted its full-year revenue outlook, while acquisition charges reduced adjusted earnings guidance.
- Higher volumes were accompanied by lower realized prices, keeping pricing pressure in focus.
Eli Lilly and Company reported strong third-quarter results on Thursday, October 29, 2026, and raised its full-year revenue outlook. The company's official release said demand for Mounjaro and Zepbound drove growth.
Revenue growth lifts full-year outlook
Revenue for the three months ended September 30 rose 39 percent year over year to USD 24.397 billion. Volume increased 53 percent, while realized prices declined 15 percent. Mounjaro generated USD 10.7 billion in quarterly revenue and Zepbound produced USD 5.3 billion.
Lilly raised its 2026 revenue guidance to USD 91 billion to USD 92 billion from USD 85 billion to USD 87 billion. Underlying non-GAAP earnings guidance improved by USD 4.07 per share at the midpoint, but acquired in-process research and development charges of USD 4.57 per share led the company to lower its reported adjusted EPS range to USD 35.00 to USD 36.00 from USD 35.50 to USD 36.50.
Pipeline adds to investor focus
The company also highlighted regulatory approvals or label expansions for Mounjaro, Onswik, Inluriyo and Jaypirca. Positive topline results for investigational retatrutide in a Phase 3 head-to-head trial against Ozempic 2 mg added another pipeline milestone.
Eli Lilly stock traded at EUR 1,275.90 on Lang & Schwarz at 4:33 p.m. Berlin time on Friday, October 30, 2026, 3.80 percent above the Xetra close of EUR 1,229.20 on Thursday, October 29, according to MarketWatch. For a direct view of the current listing, see the real-time quote of Eli Lilly and Company stock.
Eli Lilly and Company stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Lang & Schwarz price: EUR 1,275.90 at 4:33 p.m. Berlin time on October 30, 2026
- Change versus Xetra close: plus 3.80 percent
- Xetra close: EUR 1,229.20 on October 29, 2026
- Sector: Healthcare
The broader market setting is covered in current S&P 500 market reports.
More developments are available in more news and analyses on Eli Lilly and Company stock.
